Valeriana amurensis · Scientific Evidence

1. Botanical Background & Distribution

Valeriana amurensis (P. A. Smirn. ex Kom.) is a perennial herb in the Caprifoliaceae family, reaching 80–150 cm in height. It has a short, inconspicuous rhizome, an erect, unbranched stem covered with coarse hairs, and 5–7–11 pairs of pinnately compound leaves. The terminal pleiochasial cymes bear narrow triangular-ovate achenes approximately 3 mm long. Flowering occurs from June to July, with fruit maturation in July–August — a narrow annual harvest window.

The species is primarily distributed in Northeast China (Heilongjiang and Jilin provinces), the Russian Far East, and North Korea. It thrives in subalpine meadows and under larch and birch forests, preferring cool, humid climates and humus-rich, well-aerated soils.

Wild Harvest The wild population used for COZHOM Sleep Concentrate is exclusively sourced from the primeval forests of the Lesser Khingan Mountains (Xiao Xing'anling) — the easternmost distribution limit of the Valeriana genus in China. The region’s cold microclimate and humus-rich larch-forest soil enhance the accumulation of bioactive secondary metabolites.

2. Phytochemical Profile: Essential Oil & Valerenic Acid

2.1 Essential Oil Composition

Gas chromatography–mass spectrometry (GC-MS) analysis of wild Valeriana amurensis root essential oil (Zhou et al., 2006) identified 83 chemical components, of which 56 compounds were structurally confirmed — representing 68.315% of the total oil content. By comparison, the related species Valeriana fauriei yielded 93 components with 54 identified compounds (58.752%).

Additional identified compounds include α-pinene (C₁₀H₁₆), camphene (C₁₀H₁₆), linalool (C₁₀H₁₈O), and safrole (C₁₀H₁₀O₂), among others. This complex profile of mono- and sesquiterpenes, along with their oxygenated derivatives, underpins the plant’s sedative and spasmolytic activities.

2.2 Valerenic Acid Quantification (RP-HPLC)

Using reversed-phase high-performance liquid chromatography (Yang et al., 2002) with a methanol–water mobile phase (40:60, v/v), flow rate of 1.0 mL/min, and UV detection at 256 nm, researchers established a calibration curve for valerenic acid:

Valerenic acid shows excellent linearity across the concentration range of 12.5–300 µg/mL. The method achieved an average recovery rate of 97.4% with a relative standard deviation (RSD) of 2.33% (n = 5), confirming its accuracy and reproducibility for quantitative quality control.

3. Clinical Evidence: Human Efficacy & Melatonin Mechanism

3.1 Trial Design

A randomized, double-blind, placebo-controlled study (Huang et al., 2013) enrolled 66 patients with primary insomnia, divided into a valerian treatment group (n = 33) and a placebo group (n = 33), plus 33 healthy volunteers as a normal control. The valerian group received 3 g of valerian root powder three times daily for 5 treatment courses (30 days each). Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI), and plasma melatonin (MT) levels were measured via radioimmunoassay.

3.2 PSQI Outcomes

• Baseline: PSQI scores — valerian group 14.98 ± 3.64 vs. placebo 15.61 ± 1.59 (t = 0.688, P = 0.247, not significant); both significantly higher than normal controls (t = 20.976, P < 0.01).
• After 3 courses: Valerian group PSQI dropped to 9.35 ± 1.93, significantly lower than placebo (14.95 ± 2.09; t = 9.387, P < 0.01).
• After 5 courses: PSQI further declined to 5.23 ± 1.13. Overall effective rate: 96.2% (valerian) vs. 20.0% (placebo). Clinical cure rate: 22.2% vs. 0%.
• 30-day follow-up: PSQI remained stable at 5.17 ± 1.13, indicating sustained benefit without rebound insomnia.

3.3 Plasma Melatonin (MT) Upregulation

The study revealed a mechanistic link between valerian treatment and endogenous melatonin biosynthesis:

• Baseline plasma MT in insomnia patients: valerian group 42.14 ± 12.45 pg/mL vs. placebo 42.54 ± 14.12 pg/mL — both significantly lower than normal controls (57.61 ± 14.90 pg/mL; t = –2.5, P = 0.015).
• After 3 courses: valerian group MT increased to 50.04 ± 15.06 pg/mL, significantly higher than placebo (t = –12.12, P < 0.01).
• After 5 courses: MT reached 54.12 ± 15.36 pg/mL, approaching normal values.
• Correlation: Sleep quality (1/mean PSQI) showed a strong positive correlation with plasma MT levels — r = 0.926.

4. Wild Resource Scarcity: Why Every Plant Matters

The wild Valeriana amurensis used in COZHOM Sleep Concentrate is exclusively harvested from the Lesser Khingan Mountains primeval forests. Several factors make this resource exceptionally limited:

• Narrow harvest window: Collection is restricted to the July–August fruit period. Outside this window, active compound integrity declines.
• Thermal lability: The valepotriate structures (iridoid esters) contain a hemiacetal linkage that degrades at temperatures exceeding 40°C, requiring careful low-temperature processing.
• IUCN status: Valeriana amurensis is listed as Near Threatened (NT) on the IUCN Red List and in the China Biodiversity Red List – Higher Plants Volume.
• Specific habitat: The species grows only in subalpine meadows and under larch/birch forests with cool climates and humus-rich soils — a narrow ecological niche that naturally limits population size.
• Comparison with other species: While Heilongjiang Province has abundant valerian resources overall, Valeriana amurensis contains relatively lower valepotriate levels than some other medicinal valerians, meaning more plant material may be required for equivalent bioactivity — increasing collection pressure on wild stands.

5. Integrated Evidence: From Molecule to Clinical Outcome

The science of Valeriana amurensis is built on three converging lines of evidence:

1. Phytochemical validation: 83 volatile compounds identified; 56 confirmed (68.315% of oil); quantified valerenic acid via HPLC with a linear range of 12.5–300 µg/mL (r = 0.9993) and 97.4% recovery.
2. Clinical efficacy: 96.2% effective rate in primary insomnia; PSQI reduction from 14.98 to 5.23; sustained benefit at 30-day follow-up (5.17).
3. Mechanistic insight: Plasma melatonin upregulation from 42.14 to 54.12 pg/mL; strong correlation with sleep quality (r = 0.926).

These data — published in indexed, peer-reviewed journals — confirm that Valeriana amurensis is not a folk remedy but a scientifically characterized, clinically validated, and ecologically rare botanical resource.